REGULATORY
AbbVie’s Hep C Drug Viekirax Priced at 53,000 Yen Daily vs. Harvoni’s 80,000 Yen
AbbVie GK’s hepatitis C drug Viekirax (ombitasvir + paritaprevir + ritonavir) is expected to debut soon after its reimbursement listing on November 26 with a daily NHI price of 53,602.40 yen to compete with Gilead Sciences K.K.’s Harvoni (ledipasvir +…
To read the full story
REGULATORY
- AMED-Backed R&D Yielded 31 Regulatory Approvals in FY2025
July 17, 2026
- MHLW to Reconvene HSC Regulation Panel for First Time in a Year
July 17, 2026
- MHLW Allows Exceptional Concerta Pharmacy Transfers
July 17, 2026
- Japan to Consider Support for Domestic Immunoglobulin Production: Minister
July 16, 2026
- Govt Set to Amend Honebuto Draft over Inflation, MFN Language
July 16, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…





